cDNA sequence for mouse heart fatty acid binding protein, H-FABP.
Reads0
Chats0
About:
This article is published in Nucleic Acids Research.The article was published on 1989-06-12 and is currently open access. It has received 29 citations till now. The article focuses on the topics: Binding protein & Complementary DNA.read more
Citations
More filters
Journal ArticleDOI
Brain lipid-binding protein (BLBP): A novel signaling system in the developing mammalian CNS
TL;DR: It is proposed that BLBP is required for the establishment of the radial glial fiber system in developing brain, a system that is necessary for the migration of immature neurons to establish cortical layers.
Journal ArticleDOI
Structural and functional features of different types of cytoplasmic fatty acid-binding proteins
TL;DR: Article de synthese sur les donnees recentes de caracteristiques structurales et physicochimiques de divers types of proteines de liaison aux acides gras, avec la signification physiologique de ces diversites.
Journal ArticleDOI
Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization.
TL;DR: It is reported here that mice lacking heart‐type FABP (H‐FABP) exhibit a severe defect of peripheral (non‐hepatic, non‐fat) LCFA utilization, establishing a requirement for H‐FabP in cardiac intracellular lipid transport and fuel selection and a major role in metabolic homeostasis.
Journal ArticleDOI
Intracellular lipid-binding proteins and their genes
TL;DR: Intracellular lipid-binding proteins are a family of low-molecular-weight single-chain polypeptides that form 1:1 complexes with fatty acids, retinoids, or other hydrophobic ligands that are products of a large multigene family of unlinked loci distributed throughout the genome.
Journal ArticleDOI
A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice
TL;DR: The results strongly suggest that TZD-induced activation of PPAR-gamma does not directly correlate with antidiabetic (glucose-lowering) action, and a new derivative, NC-2100, is a weak PPAR -gamma activator.